M W M Wintergerst1, J Bouws2, J Loss3, B Heimes4, D Pauleikhoff4, F G Holz1, R P Finger5. 1. Universitäts-Augenklinik Bonn, Bonn, Deutschland. 2. AMD-Netz, Münster, Deutschland. 3. Medizinische Soziologie, Institut für Epidemiologie und präventive Medizin, Universität Regensburg, Regensburg, Deutschland. 4. St. Franziskus-Hospital Münster, Münster, Deutschland. 5. Universitäts-Augenklinik Bonn, Bonn, Deutschland. robert.finger@ukbonn.de.
Abstract
BACKGROUND: Critical prerequisites for successful therapy of neovascular age-related macular degeneration (nvAMD) are an early initiation and continuous monitoring; however, delays in starting therapy and non-medically indicated discontinuation of therapy are frequent, which limits therapy efficacy and, thus, visual outcomes. OBJECTIVE: To identify the reasons for delay in therapy and non-medically indicated termination of therapy. MATERIAL AND METHODS: Patients who had started a new therapy (starters) and those who independently terminated therapy (dropouts) were interviewed by telephone with a specific, standardized questionnaire. Results were summarized descriptively. RESULTS: A total of 100 starters and 55 dropouts were interviewed. The mean therapy delay was 22 (±28 SD) days. This was mainly due to the time until the decision to see an ophthalmologist was made. Main reasons for dropping out were: transportation issues (27%), poor general health (25%) and the assumption that there is no benefit from therapy (11%). Of the patients who dropped out 63% would have liked to continue therapy. CONCLUSION: There is potential for improvement in nvAMD management regarding therapy start as well as therapy maintenance. Sensitizing for initial nvAMD symptoms is important as is reduction of barriers to therapy maintenance, since most therapy dropouts would like to continue the therapy.
BACKGROUND: Critical prerequisites for successful therapy of neovascular age-related macular degeneration (nvAMD) are an early initiation and continuous monitoring; however, delays in starting therapy and non-medically indicated discontinuation of therapy are frequent, which limits therapy efficacy and, thus, visual outcomes. OBJECTIVE: To identify the reasons for delay in therapy and non-medically indicated termination of therapy. MATERIAL AND METHODS:Patients who had started a new therapy (starters) and those who independently terminated therapy (dropouts) were interviewed by telephone with a specific, standardized questionnaire. Results were summarized descriptively. RESULTS: A total of 100 starters and 55 dropouts were interviewed. The mean therapy delay was 22 (±28 SD) days. This was mainly due to the time until the decision to see an ophthalmologist was made. Main reasons for dropping out were: transportation issues (27%), poor general health (25%) and the assumption that there is no benefit from therapy (11%). Of the patients who dropped out 63% would have liked to continue therapy. CONCLUSION: There is potential for improvement in nvAMD management regarding therapy start as well as therapy maintenance. Sensitizing for initial nvAMD symptoms is important as is reduction of barriers to therapy maintenance, since most therapy dropouts would like to continue the therapy.
Authors: Jonathan H Lim; Sanjeewa S Wickremasinghe; Jing Xie; Devinder S Chauhan; Paul N Baird; Luba D Robman; Gregory Hageman; Robyn H Guymer Journal: Am J Ophthalmol Date: 2012-01-14 Impact factor: 5.258
Authors: Philipp S Muether; Robert Hoerster; Manuel M Hermann; Bernd Kirchhof; Sascha Fauser Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-05-11 Impact factor: 3.117
Authors: Tatiana Dubayova; Jitse P van Dijk; Iveta Nagyova; Jaroslav Rosenberger; Eva Havlikova; Zuzana Gdovinova; Berrie Middel; Johan W Groothoff Journal: Int J Public Health Date: 2010-05-14 Impact factor: 3.380
Authors: J Stasch-Bouws; S M Eller-Woywod; S Schmickler; J Inderfurth; P Hoffmann; C Ohlmeyer; B Kammering; D Pauleikhoff Journal: Ophthalmologe Date: 2020-04 Impact factor: 1.059
Authors: Henrik Faatz; Marie-Louise Gunnemann; Kai Rothaus; Marius Book; Matthias Gutfleisch; Albrecht Lommatzsch; Daniel Pauleikhoff Journal: Ophthalmologe Date: 2021-02 Impact factor: 1.059
Authors: Maximilian Pfau; Soumya Sahu; Rawan Allozi Rupnow; Kathleen Romond; Desiree Millet; Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein; Jennifer I Lim; Luis de Sisternes; Theodore Leng; Daniel L Rubin; Joelle A Hallak Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283